Clinical Trial Update: Promoting Repigmentation After Epidermal Cell Suspension Grafting and preVENTing the Loss of Melanocytes Using Topical Ruxolitinib for Vitiligo in Resistant Areas [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating topical ruxolitinib to promote repigmentation after epidermal cell suspension grafting and prevent loss of melanocytes in re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vitiligo

Drugs mentioned

• Topical ruxolitinib (ruxolitinib)

Snippet

Sponsor: Centre Hospitalier Universitaire de Nice | Conditions: Vitiligo | Phase 2 | Status: COMPLETED